319014-58-9

Basic information

• Product Name: 2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-OL
• Synonyms: 2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-OL;AKOS BH-1354;4-(2-Trifluoromethylphenyl)phenol
• CAS NO: 319014-58-9
• Molecular Formula: C13H9F3O
• Molecular Weight: 238.21
• Mol File: 319014-58-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 319.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.276±0.06 g/cm3(Predicted)
• PKA: 9.51±0.15(Predicted)
• CAS DataBase Reference: 2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-OL(319014-58-9)
• EPA Substance Registry System: 2'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-4-OL(319014-58-9)

Safety Data

• Hazardous Substances Data: 319014-58-9(Hazardous Substances Data)

Usage

Structure

Contains a biphenyl group and a trifluoromethyl group

Classification

Organic phenolic compound

Usage

Different sources of media describe the Usage of 319014-58-9 differently. You can refer to the following data:
1. Commonly used in the pharmaceutical industry as a building block for synthesizing various pharmaceutical drugs
2. Used as a reagent in organic synthesis
3. Serves as a starting material for the preparation of other organic compounds

Potential applications

Has potential applications in the field of medicinal chemistry and drug discovery due to its unique structure and pharmacological properties.

Upstream product

• 88-16-4 1-chloro-2-(trifluoromethyl)benzene 
• 25244-30-8 4-(allyloxy)bromobenzene 
• 1423-27-4 2-(trifluoromethyl)phenylboronic acid 
• 106-41-2 4-bromo-phenol 
• 67963-68-2 t-butyldimethylsilyl-4-bromophenol 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 123088-32-4 4-tert-butyl-dimethylsilyloxyphenylboronic acid anhydride 

Relevant articles and documents

NOVEL HYDROXYPHENYL BORONIC ESTER, MANUFACTURING METHOD THEREFOR, AND MANUFACTURING METHOD OF HYDROXYPHENYL COMPOUND

PROBLEM TO BE SOLVED: To provide a hydroxyphenyl boronic ester, a manufacturing method therefor and a biphenyl compound using the hydroxyphenyl boronic ester. SOLUTION: There are provided a manufacturing method for producing a compound of the formula (1) by reacting tertiary halogenobenzene of the formula (4) and boronic ester of the formula (3) to synthesize tertiary alkoxyphenyl boron ester of the formula (2) and reacting it with acid, and further a manufacturing method of a hydroxy biphenyl compound of the formula (7) by a Suzuki coupling reaction with an aryl halogen compound or the like. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Structural modification of honokiol, a biphenyl occurring in magnolia officinalis: The evaluation of honokiol analogues as inhibitors of angiogenesis and for their cytotoxicity and structure-activity relationship

Honokiol, widely known as an antitumor agent, has been used as an antiangiogenesis drug lead. In this paper, 47 honokiol analogues and derivatives were investigated for their antiangiogenic activity by application of the transgenic zebrafish screening model, antiproliferative and cytotoxic activity against HUVECs, and three tumor cell lines by MTT assay. 3′,5-Diallyl-2, 4′-dihydroxy-[1,1′-biphen-yl]-3,5′-dicarbaldehyde (8c) was found to suppress the newly grown segmental vessels from the dorsal aorta of zebrafish and prevent inappropriate vascularization as well as exhibit more potent inhibitory effects on the proliferation of HUVECs, A549, HepG2, and LL/2 cells (IC50 = 15.1, 30.2, 10.7, and 21.7 μM, respectively) than honokiol (IC50 = 52.6, 35.0, 16.5, and 65.4 μM, respectively). Analogue 8c also effectively inhibited the migration and capillary-like tube formation of HUVECs in vitro. The antiangiogenic effect and antiproliferative activity of these structurally modified honokiol analogues and derivatives have led to the establishment of a structure-activity relationship.

ERbeta ligands. Part 1: the discovery of ERbeta selective ligands which embrace the 4-hydroxy-biphenyl template.

The synthesis and structure-activity relationships of a series of simple biphenyls is described. Optimization of the 4-hydroxy-biphenyl template led to compounds with ERbeta selectivity on the order of 20-70-fold.